Originator: Eli Lilly and Company

First marketed by: Eli Lilly and Company

Name of FDF: Mounjaro®

Original FDF: RTU solution for subcutaneous injection

Mode of Action
dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist

Indications
Type 2 diabetes mellitus

Patent status
Subcutaneous formulation is still patented until 2032-05-13